At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
JNJ-55308942 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
In Brief
A Phase 2 clinical trial evaluating JNJ-55308942 and Placebo for Bipolar Disorder. Completed, enrolled 116 participants across 44 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder
CountriesCanada, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartJun 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedApr 14, 2022
Enrollment StartJun 3, 2022
Primary CompletionMay 17, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.2 years ago
Interventions
JNJ-55308942drug
JNJ-55308942 capsules will be administered orally.
Placebodrug
Matching placebo capsules will be administered orally.